US Biosimilar Marketplace Investigated in New Kuick Research Report Available at MarketPublishers.com
23 Feb 2016 • by Natalie Aster
LONDON – Biosimilars (or follow-on biologics, biopharmaceuticals) in USA were approved after a long time after they were introduced to other countries over 10 years ago. Late entry in the domestic market has stopped the patients from reaping the benefits from biosimilars. Furthermore, healthcare expenditure could have been mitigated but the absence of the appropriate regulatory framework prevented biosimilars from getting commercialised across the USA. The biosimilar are currently approved for few indications, and this is likely to have a moderate effect on the national market. Still, the number of indications is poised to grow in the years to come; until then, the US biosimilar market is forecast to post moderate growth. Sluggish market growth is a matter of great concern as it also pertains to healthcare cost reductions by regulators.
In the US market, newly developed biosimilars are anticipated to face difficult times as regulations are still not in place. Payers and patients alike will likely suffer from this issue that has to be settled in the shortest possible time. Implication of novel rules is set to take up some time as a great many issues have to be tackled. Naming of these follow-on biologics and assigning of adequate billing code is one of the paramount needs. This situation will likely take a turn for the worse after the introduction of monoclonal antibodies to US market. Replacement and reimbursement will become easier in case accurate demarcation is made between which molecule belongs to which category. Respective regulatory authorities are projected to resolve these issues in the offing as they have just come into the biosimilars market.
New market research report “US Biosimilars Market Opportunity & Clinical Pipeline Analysis” developed by Kuick Research offers comprehensive examination of the US market for biosimilars. The study looks into the US biosimilars regulatory scenario, specific features of the country’s biosimilars market, influence of biosimilars in US market, impact of reimbursement policies on the market, novel biosimilar categories with high commercialisation potential, and the middle ground between biosimilars and biologics. The study gives an overview of the US biosimilars market covering the current market scenario and biosimilar clinical pipeline. First Approved Biosimilar in US – Zarxio – is carefully discussed. The study then analyses the US biosimilar clinical pipeline by firm, indication & phase; reviews the 104 biosimilars in development; and limelights 1 marketed biosimilar. The research report canvasses the competitive scene alongside profiling the 22 leading players.
US Biosimilars Market Opportunity & Clinical Pipeline Analysis
Published: February, 2016
Price: US$ 2,400.00
More studies by the publisher can be found at Kuick Research page.